HLA-E/human β2-microglobulin transgenic pigs: Protection against xenogeneic human anti-pig natural killer cell cytotoxicity

Transplantation

Volumn 87, Issue 1, 2009, Pages 35-43

  Weiss, Elisabeth H ^a   Lilienfeld, Benjamin G ^b   Müller, Sigrid ^a   Müller, Elfriede ^a   Herbach, Nadja ^a   Keßler, Barbara ^a   Wanke, Rüdiger ^a   Schwinzer, Reinhard ^c   Seebach, Jörg D ^b   Wolf, Eckhard ^a   Brem, Gottfried ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

2 microglobulin; HLA E; NK cell; Transgenic pig; Xenotransplantation

Indexed keywords

BETA 2 MICROGLOBULIN; CD94 ANTIGEN; GAMMA INTERFERON; HLA B7 ANTIGEN; HLA E ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENOMIC FRAGMENT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOBLAST; NATURAL KILLER CELL; NONHUMAN; NORTHERN BLOTTING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA ANALYSIS; TRANSGENIC PIG; WESTERN BLOTTING; ZYGOTE; ANIMAL; ANTIBODY SPECIFICITY; CELL CULTURE; CELL MOTION; CYTOLOGY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; SWINE; TRANSGENIC ANIMAL; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BETA 2-MICROGLOBULIN; CELL MOVEMENT; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIAL CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; ORGAN SPECIFICITY; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 58949084485     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318191c784     Document Type: Article

References (39)

1. Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 2004; 101: 7335.
2. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089.
3. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411.
4. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: Initial experience. Nat Med 2005; 11: 29.
5. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3- galactosyltransferase gene-knockout donors and the co-transplantation of vascularized thymic tissue. Nat Med 2005; 11: 32.
6. Cascalho M, Platt JL. The immunological barrier to xenotransplantation. Immunity 2001; 14: 437.
7. Inverardi L, Pardi R. Early events in cell-mediated recognition of vascularized xenografts: Cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141: 71.
8. Khalfoun B, Barrat D, Watier H, et al. Development of an ex vivo model of pig kidney perfused with human lymphocytes. Analysis of xenogeneic cellular reactions. Surgery 2000; 128: 447.
9. Rieben R, Seebach JD. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005; 26: 2.
10. Schneider MK, Seebach JD. Current cellular innate immune hurdles in pig-to-primate xenotransplantation. Curr Opin Organ Transplant 2008; 13: 171.
11. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19: 291.
12. Garcia P, Llano M, de Heredia AB, et al. Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol 2002; 32:936.
13. Lilienfeld BG, Crew MD, Forte P, et al. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Xenotransplantation 2007; 14: 126.
14. Matsunami K, Miyagawa S, Nakai R, et al. Modulation of the leader peptide sequence of the HLA-E gene up-regulates its expression and down-regulates natural killer cell-mediated swine endothelial cell lysis. Transplantation 2002; 73: 1582.
15. Sasaki H, Xu XC, Mohanakumar T. HLA-E and HLA-G expression on porcine endothelial cells inhibit xenoreactive human NK cells through CD94/NKG2-dependent and -independent pathways. J Immunol 1999; 163: 6301.
16. Strong RK, Holmes MA, Li P, et al. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003; 278: 5082.
17. Ulbrecht M, Couturier A, Martinozzi S, et al. Cell surface expression of HLA-E: Interaction with human beta2-microglobulin and allelic differences. Eur J Immunol 1999; 29: 537.
18. Miller JD, Weber DA, Ibegbu C, et al. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J Immunol 2003; 171: 1369.
19. Pacasova R, Martinozzi S, Boulouis HJ, et al. Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. J Immunol 1999; 162: 5190.
20. Klose R, Kemter E, Bedke T, et al. Expression of biologically active human TRAIL in transgenic pigs. Transplantation 2005; 80: 222.
21. Besenfelder U, Modl J, Muller M, et al. Endoscopic embryo collection and embryo transfer into the oviduct and the uterus of pigs. Theriogenology 1997; 47: 1051.
22. Engler-Blum G, Meier M, Frank J, et al. Reduction of background problems in nonradioactive Northern and Southern blot analyses enables higher sensitivity than 32P-based hybridizations. Anal Biochem 1993; 210: 235.
23. Lee N, Goodlett DR, Ishitani A, et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998; 160: 4951.
24. Seebach JD, Schneider MK, Comrack CA, et al. Immortalized bone-marrow derived pig endothelial cells. Xenotransplantation 2001; 8: 48.
25. Seebach JD, Comrack C, Germana S, et al. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655.
26. Ulbrecht M, Honka T, Person S, et al. The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol 1992; 149: 2945.
27. Maier S, Grzeschik M, Weiss EH, et al. Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol 2000; 61: 1059.
28. Dulat HJ, von Grumbkow C, Baars W, et al. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol 2001; 31: 2217.
29. Sharland A, Patel A, Lee JH, et al. Genetically modified HLA class I molecules able to inhibit human NK cells without provoking alloreac-tive CD8+ CTLs. J Immunol 2002; 168: 3266.
30. Crew MD, Cannon MJ, Phanavanh B, et al. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol Immunol 2005; 42: 1205.
31. Trowsdale J. HLA genomics in the third millennium. Curr Opin Immunol 2005; 17: 498.
32. Vales-Gomez M, Reyburn HT, Erskine RA, et al. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/ NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 1999; 18: 4250.
33. Lilienfeld BG, Garcia-Borges C, Crew MD, et al. Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D. J Immunol 2006; 177: 2146.
34. Sutherland CL, Chalupny NJ, Cosman D. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol Rev 2001; 181: 185.
35. Forte P, Baumann BC, Weiss EH, et al. HLA-E expression on porcine cells: Protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5: 2085.
36. Adams DH, Kadner A, Chen RH, et al. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 2001; 8: 36.
37. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
38. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
39. Cowan PJ, d'Apice AJ. The coagulation barrier in xenotransplantation: Incompatibilities and strategies to overcome them. Curr Opin Organ Transplant 2008: 13: 178.